Related Experiment Video
Updated: Apr 11, 2026
Subtyping of Campylobacter jejuni ssp. doylei Isolates Using Mass Spectrometry-based PhyloProteomics MSPP
Published on: October 30, 2016
Multi-omics and machine learning-based profiling of severity signatures in Mycoplasma pneumoniae infection in
Guiqiu Li1, Ying Wei2, Wenzheng Wang1
1Shenzhen Nanshan People's Hospital and Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China.
Abstract:
Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children; however, the mechanisms driving its progression to severe disease remain poorly understood. This study employs a comprehensive proteomic and metabolomic approach to elucidate severity-related pathways and identify potential biomarkers for improved diagnosis and targeted therapy. By analyzing blood proteomes from pediatric patients with varying MPP severities alongside healthy controls, and integrating multi-omics data from bronchoalveolar lavage fluid (BALF), we uncovered key severity-associated proteins and metabolites linked to inflammatory and metabolic dysregulation such as efferocytosis pathway, and Fanconi anemia pathway. Machine learning analysis further identified 8 critical biomarkers that accurately distinguished between mild and severe MPP cases. The identification of severity-specific biomarkers offers a foundation for enhanced diagnostic precision, improved disease stratification, and the development of targeted therapeutic strategies to optimize the management of severe MPP in pediatric patients.
Insights
This study identifies key protein and metabolite biomarkers linked to severe pediatric Mycoplasma pneumoniae pneumonia (MPP). These findings pave the way for better diagnosis and targeted treatments for severe respiratory infections.
Area of Science:
- Pediatric Pulmonology
- Translational Medicine
- Biomarker Discovery
Background:
- Mycoplasma pneumoniae pneumonia (MPP) is a frequent pediatric respiratory illness.
- Mechanisms underlying progression to severe MPP are not well understood.
- Improved diagnostics and targeted therapies are needed for severe MPP.
Purpose of the Study:
- To elucidate severity-related pathways in pediatric MPP using multi-omics.
- To identify potential biomarkers for improved diagnosis and targeted therapy.
- To stratify disease severity and guide therapeutic strategies.
Main Methods:
- Comprehensive proteomic and metabolomic analysis of blood samples from pediatric MPP patients and healthy controls.
- Integration of multi-omics data from bronchoalveolar lavage fluid (BALF).
- Machine learning analysis to identify severity-specific biomarkers.
Main Results:
- Identified key severity-associated proteins and metabolites.
- Uncovered links to inflammatory and metabolic dysregulation, including efferocytosis and Fanconi anemia pathways.
- Discovered 8 critical biomarkers distinguishing mild from severe MPP cases with high accuracy.
Conclusions:
- The identified biomarkers provide a foundation for enhanced diagnostic precision in pediatric MPP.
- Biomarkers enable improved disease stratification for better patient management.
- Findings support the development of targeted therapeutic strategies for severe MPP.
